This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Singh, R. Articles by Paterson, Y. Search for Related Content PubMed PubMed Citation Articles by Singh, R. Articles by Paterson, Y.

Immunoediting Sculpts Tumor Epitopes during Immunotherapy

Department of Microbiology, University of Pennsylvania, Philadelphia, Pennsylvania

Requests for reprints: Yvonne Paterson, Department of Microbiology, University of Pennsylvania School of Medicine, 323 Johnson Pavilion, 36th Street and Hamilton Walk, Philadelphia, PA 19104-6076. Phone: 215-898-3461; Fax: 215-573-4666; E-mail: yvonne{at}mail.med.upenn.edu.

Immunoediting of tumor-associated antigens occurs in response to immune pressure. We show that the mutation of residues within epitopes of HER-2/neu leads to the outgrowth of autochthonous tumors after immunizing HER-2/neu transgenic mice with Listeria monocytogenes therapeutic vaccines expressing fragments of HER-2/neu. Three of these vaccines target the extracellular domain (LmLLO-EC1, LmLLO-EC2, and LmLLO-EC3), and two of these vaccines target the intracellular domain (Lm-LLO-IC1 and Lm-LLO-IC2). Mutations occurred in the regions of the HER-2/neu molecule targeted by the Listeria strain expressing that region, which suggests that the rate of generation of escape mutants was a significant factor in the efficacy of each vaccine. A longer delay in the onset of tumors after immunotherapy occurred with the vaccine that targeted the kinase domain. We verified that the mutations in this domain occurred within novel CD8⁺ T-cell epitopes, and that the mutation of these residues abrogated CTL responses to these epitopes. The long delay in the onset of tumors after immunotherapy targeting the kinase domain may be because this region of HER-2/neu cannot undergo extensive mutations without impairing its ability to signal cell growth. [Cancer Res 2007;67(5):1887–92]

This article has been cited by other articles:

				M. M. Seavey, P. C. Maciag, N. Al-Rawi, D. Sewell, and Y. Paterson An Anti-Vascular Endothelial Growth Factor Receptor 2/Fetal Liver Kinase-1 Listeria monocytogenes Anti-Angiogenesis Cancer Vaccine for the Treatment of Primary and Metastatic Her-2/neu+ Breast Tumors in a Mouse Model J. Immunol., May 1, 2009; 182(9): 5537 - 5546. [Abstract] [Full Text] [PDF]

				M. M. Seavey, Z.-K. Pan, P. C. Maciag, A. Wallecha, S. Rivera, Y. Paterson, and V. Shahabi A Novel Human Her-2/neu Chimeric Molecule Expressed by Listeria monocytogenes Can Elicit Potent HLA-A2 Restricted CD8-positive T cell Responses and Impact the Growth and Spread of Her-2/neu-positive Breast Tumors Clin. Cancer Res., February 1, 2009; 15(3): 924 - 932. [Abstract] [Full Text] [PDF]

				H. Conrad, K. Gebhard, H. Kronig, J. Neudorfer, D. H. Busch, C. Peschel, and H. Bernhard CTLs Directed against HER2 Specifically Cross-React with HER3 and HER4 J. Immunol., June 15, 2008; 180(12): 8135 - 8145. [Abstract] [Full Text] [PDF]

				P. Nanni, G. Nicoletti, A. Palladini, S. Croci, A. Murgo, A. Antognoli, L. Landuzzi, M. Fabbi, S. Ferrini, P. Musiani, et al. Antimetastatic Activity of a Preventive Cancer Vaccine Cancer Res., November 15, 2007; 67(22): 11037 - 11044. [Abstract] [Full Text] [PDF]